- SELLAS Life Sciences Group Inc (NASDAQ: SLS) announced results from a new preclinical in vitro study for its highly selective CDK9 inhibitor, GFH009, in neuroendocrine prostate cancer (NEPC).
- The data shows that GFH009 demonstrated significant anti-tumor effects in the selected cell line at nanomolar concentrations and, in certain samples, complete growth inhibition with no viable cancer cells.
- Also See: SELLAS Life Sciences's Galinpepimut/Opdivo Combo Shows Increased Survival In Mesothelioma Patients.
- NEPC is an aggressive variant of prostate cancer. In up to 15%-20% of patients treated with hormonal therapies for prostate adenocarcinoma, small-cell prostate cancer may develop in later stages of prostate cancer progression.
- Median survival for NEPC patients whose cancer arose from prior prostate adenocarcinoma is estimated at only 5.4 months.
- The conversion to NEPC is associated with recurrent genetic lesions, including mutation or deletion of RB1 and TP53 and the overexpression and genomic amplification of MYCN.
- Price Action: SLS shares are up 0.83% at $3.35 on the last check Wednesday.
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
